Aldeyra Therapeutics获得欧洲药品管理局孤儿药指定,其ADX-2191用于治疗免疫特权部位原发性大B细胞淋巴瘤,包括原发性玻璃体视网膜淋巴瘤

美股速递
Aug 28, 2025

Aldeyra Therapeutics获得欧洲药品管理局孤儿药指定,其ADX-2191用于治疗免疫特权部位原发性大B细胞淋巴瘤,包括原发性玻璃体视网膜淋巴瘤。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10